Onclive Team

Dr. Renato G. Martins talks about the impact of nivolumab, an anti–PD-1, and ipilimumab, an anti CTLA-4, in the treatment of lung cancer.

OncLive is proud to announce that nominations are open for the 4th Annual Giants of Cancer Care awards. The Giants of Cancer Care program celebrates the achievements of leading physicians and researchers who have devoted their time, talent and resources to improving care for the many patients and their families affected by cancer.

Clinical trial designs are transforming dramatically in order to expedite the discovery and validation of new predictive biomarkers for patients with non–small cell lung cancer and other types of solid tumors.

The impact upon cancer care, made by Paul Bunn, MD, extends far beyond the programs he helped build in Colorado.

The oral corticosteroid dexamethasone significantly decreased flares of bone pain when added to radiation therapy in patients with metastatic cancer.

The additon of hormonal therapy to salvage radiotherapy demonstrated a significant survival benefit in patients with prostate cancer recurrence after radical prostatectomy, according to long-term follow-up data from a randomized trial.

The progression-free survival benefit with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer was observed across common sites of metastasis.

Medical oncologist Lori J. Goldstein, MD, from Fox Chase Cancer Center, have been looking at reparixin, an investigational study drug that targets breast cancer stem cells.

Most patients with non-small cell lung cancer (NSCLC) that has metastasized to the brain have a dire prognosis.

The National Cancer Institute has named Craig Crews, PhD, a recipient of its Outstanding Investigator Award.

Kentucky's only NCI cancer center, Markey focuses on bringing the latest therapies to its home state.

The nation's leading digital and print resource for oncology professionals, OncLive, announced today it is doubling the frequency of its flagship publication, OncologyLive, to keep pace with the quickly evolving oncology marketplace. Starting in January, the clinical news publication will publish twice a month, with expanded coverage of emerging therapeutic strategies and research developments.

Internationally renowned clinician-scientist Alec Kimmelman, MD, PhD, has been named Chair of the Department of Radiation Oncology at NYU Langone Medical Center. His appointment is effective February 1, 2016.

Videos from the 5th International Adrenal Cancer Conference

OncLive, the nation's leading digital and print resource for oncology professionals, will introduce its new peer-reviewed journal, Contemporary Radiation Oncology, at the 57th annual meeting of the American Society of Radiation Oncology (ASTRO), which will be held October 18-21 in San Antonio, Texas.

Protein engineering expert Shohei Koide, PhD, appointed Director of Cancer Biologics at Perlmutter Cancer Center to lead groundbreaking new initiative in growing field of research and therapeutics

Regional Cancer Care Associates, LLC, will now provide cancer care to patients in Maryland through four divisions in the greater Washington, DC area.

Collaboration to share the latest news from The US Oncology Network, a physician-led organization uniting top oncology practices across the nation to deliver high-quality, evidence-based cancer care

The FDA has granted an orphan drug designation to the next-generation hypomethylating agent guadecitabine as a potential treatment for patients with acute myeloid leukemia.

Overall survival was improved by more than 25 months when lyso-thermosensitive liposomal doxorubicin was administered with optimized (≥45 minutes dwell time) radiofrequency ablation in patients with hepatocellular carcinoma.

Five years from now multiple myeloma will have a therapeutic backbone consisting entirely of combinations of novel agents.

The antibody-drug conjugate rovalpituzumab tesirine demonstrated activity across a range of patients with relapsed and refractory small-cell lung cancer.

Data from the pivotal KEYNOTE-001 trial showing pembrolizumab's efficacy in pretreated non–small cell lung cancer (NSCLC) were presented at the 2015 European Cancer Congress, just days before the FDA is scheduled to make its approval decision on the PD-1 inhibitor in this setting.

The combination of the attenuated oncolytic virus talimogene laherparepvec and the immune checkpoint inhibitor pembrolizumab for unresectable melanoma has passed an early safety evaluation.

Two strategies of sequential immunotherapy for advanced melanoma showed similar safety and tolerability but substantially different efficacy.

More than half of brain metastases harbored clinically actionable genetic alterations that were distinct from those associated with the primary tumor.

More than a fifth of patients with previously treated metastatic nasopharyngeal carcinoma showed a measurable response when treated with the immune checkpoint inhibitor pembrolizumab.

Bart Barlogie, MD, world-renowned myeloma expert who introduced the first curative therapy, a multi-drug regimen known as Total therapy 3, for multiple myeloma joins the faculty of Tisch Cancer Institute of the Icahn School of Medicine at Mount Sinai.

The heterogeneity of mantle cell lymphoma will require new combination strategies to improve outcomes.

Lack of improvement in failure-free survival for patients with follicular lymphoma has fueled interest in new treatment strategies that might offer promise of better outcomes.